Philip Morris International Inc. — FY 2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. The request identifies 2012 Q4, but this filing is an annual report; the provided text does not include a complete standalone fourth-quarter financial summary.
Business context
PMI is a Virginia holding company whose subsidiaries and affiliates manufacture and sell tobacco products outside the United States. Products were sold in more than 180 markets. Marlboro represented approximately 33% of PMI’s 2012 shipment volume; international brands represented approximately 70%.
- Cigarette shipments rose 1.3% to 927.0 billion units. PMI estimated international market shipments grew 0.7%.
- Estimated international cigarette market share increased to 16.3% from 16.2% in 2011; excluding China, it rose to 28.8% from 28.3%.
- Marlboro shipments increased 0.5%.
Financial performance and liquidity
The supplied filing text incorporates the statements of earnings, cash flows, balance sheets, selected financial data and detailed MD&A by reference to PMI’s 2012 Annual Report, but does not reproduce their figures. Revenue, profit, margins, cash flow, debt balances and liquidity measures therefore cannot be stated clearly from the provided text.
PMI evaluates geographic segments using operating companies income. The 2012 shares of that measure were Asia 36.7%, EU 29.6%, EEMA 26.3%, and Latin America & Canada 7.4%. Asia’s share increased from 35.5% in 2011, while the EU share declined from 33.5%; these are shares of segment operating companies income, not reported growth rates.
PMI completed a $12 billion share-repurchase program in July 2012 and began an $18 billion, three-year program on August 1. It repurchased approximately 22.4 million shares in Q4 at an average price of $87.58. The filing listed revolving credit facilities of $3.5 billion and $2.5 billion; drawn amounts and period-end debt are not clear in the supplied text.
Changes, outlook and management commentary
- PMI launched a revised consumer-focused marketing and sales framework during 2012.
- PMI was developing non-combustion next-generation products (NGPs), targeting commercialization in 2016–2017. It planned one or two European manufacturing facilities, with expected capital expenditures of €500–600 million over three years and initial capacity of approximately 30 billion units annually.
- The company reported no business acquisitions in 2012.
- Management said tobacco supply was adequate for anticipated production needs. The filing text does not provide a quantified earnings or revenue forecast.
Risks, contingencies and unusual items
- Key risks include higher tobacco taxes, stricter product and marketing regulation, declining smoking acceptance and consumption, downtrading, illicit trade, intense competition, foreign-exchange movements, political and economic instability, agricultural supply and climate variability, and cybersecurity or third-party service disruption.
- Tobacco-related litigation remained material and uncertain. As of February 15, 2013, PMI reported 75 individual smoking-and-health cases, 11 smoking-and-health class actions, 15 health-care cost recovery cases, two “lights” class actions, one individual “lights” case, and four public civil actions.
- PMI stated that no loss was considered probable and estimable for pending tobacco-related cases; accordingly, no estimated loss for unfavorable outcomes was accrued. Management said an adverse outcome could materially affect a particular period’s results, cash flows or financial position.
- Management did not expect other ordinary-course litigation or environmental expenditures to have a material adverse effect. The filing warns that this assessment does not eliminate the possibility of material adverse developments.
Important facts for investors to verify
- Consult the incorporated 2012 Annual Report for actual revenue, earnings, margins, cash flows, balance-sheet liquidity, debt, and full year-over-year comparisons.
- Review currency effects, excise-tax impacts and segment operating results in the complete MD&A.
- Track the $18 billion repurchase program, dividends, debt maturities and available credit facility capacity.
- Monitor NGP development, commercialization timing and planned €500–600 million investment.
- Follow major tobacco litigation, regulatory changes, tax increases and illicit-trade trends, particularly in markets with significant exposure.